We are pleased to announce our investment in REDUCED, a Copenhagen-based company that uses fermentation technology to transform food and agriculture industry side streams into natural food ingredients.

A total of EUR 6 million in new financing has been raised from a range of

We are pleased to join lead investor Wellington Management in Obsidian Therapeutics’ oversubscribed USD $160.5 million Series C financing. Proceeds from this financing will help advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in patients

Today, the Asia Investments Team publishes its Annual Review. In 2023, the team experienced increasing momentum, expanding its portfolio of investments, growing the team, and fostering new partnerships. Notable achievements include three new portfolio company investments and two

Clasp Therapeutics is a biotechnology company bringing unparalleled precision to immune-oncology through next-generation T cell engagers, and we are pleased to co-lead their US $150 million Series A financing, together with Catalio Capital Management and Third Rock Ventures. Clasp is leveraging

In 2023, Novo Holdings reaffirmed its commitment to a more sustainable future for all with the establishment of the Bioindustrial Investments team, which now oversees a dynamic portfolio of 23 companies.
Through substantial investments, we have solidified Novo Holdings’ position

We continue our support for Asgard Therapeutics as an investor in their Series A financing, co-led by RV Invest and Johnson & Johnson Innovation. Asgard leads the field of in vivo cell reprogramming to treat cancer, with a unique approach to turn tumor cells into immune cells. 

In their earlier

Today Amolyt Pharma announced an agreement to be acquired by AstraZeneca. Novo Holdings co-led  Amolyt's Series A financing in 2019 at preclinical stage and is the Company’s largest shareholder.  Alongside our Board representation, we have supported the Company through

Our 2023 results presented by CEO Kasim Kutay

We are pleased to share our Annual Results for 2023.

Our Total Income and Returns for 2023 are DKK 31 billion (€4.2 billion) and our Total Assets increased by 38% to DKK 1,114 billion (€149 billion), reflecting a strong performance both from the Novo Group companies and from

At Novo Holdings, our goal is to foster an environment that not only embraces diversity and inclusion but also empowers women to succeed. This International Women's Day, we reflect on our progress toward advancing gender diversity with pride, while staying focused on the

2023 was a record year for the Novo Holdings Venture Investments team as it continued its mission to advance innovative therapies for patients. The team added 18 new portfolio investments and completed the acquisition of five portfolio companies. With $766 million invested and

Novo Holdings is proud to announce the launch and €26 million seed financing of Orbis Medicines, a leader in oral macrocycle drug development. Alongside European life sciences venture firm Forbion, this funding will support Orbis’ expansion and advancement of its portfolio of

Novo Holdings is pleased to announce the appointment of Mauricio Graber to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its investments. With his extensive background and broad executive

Novo Holdings today announced its investment in Manipal Hospitals which constitutes our largest investment in Asia to date.

Manipal Hospitals is among the top healthcare providers in India, offering comprehensive curative and preventive care for patients within India and from

We are pleased to announce that we have entered into an agreement to acquire Catalent Pharma Solutions, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

We are pleased to share that Medi Assist has successfully completed its IPO and is now listed on the two main stock exchanges in India – the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Novo Holdings invested in Medi Assist prior to its IPO, marking

Novo Holdings CEO Kasim Kutay talked to Bloomberg’s Francine Lacqua at #worldeconomicforum in Davos.
Among other topics, Kasim discussed how Novo Holdings will be scaling its investment activities, trends in the healthcare sector and the broader macro environment.

The Novo Holdings Growth Investments team led a USD $75 million financing round in Cleveland Diagnostics, a cancer biotechnology company developing highly efficacious, clinician-friendly diagnostics tests that detect prostate cancer earlier.

“Currently 1 in every 8 men are